Techne Corporation to acquire 100% ownership of Bionostics Holdings Limited

| Printer friendly version

According to a company press release, Techne Corporation has agreed to acquire a 100% ownership stake of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. for $104 million in cash.

The press release identifies Bionostics as “a global leader in the development, manufacture and distribution of control solutions that verify the proper operation of in vitro diagnostic (IVD) devices primarily utilized in point of care blood glucose and blood gas testing.”  Techne, through its subsidiaries R&D Systems and R&D Systems Europe, describes itself as involved in “the development, manufacture, and sale of biotechnology products and hematology calibrators and controls.”

According to the press release, the acquisition is expected to close in the first quarter of fiscal year 2014.  After the close of the transaction, the Bionostics and Techne’s Hematology Division “will collectively operate under a new Clinical Controls Division of R&D Systems.”

The press release states:

Controls for blood glucose and blood gas devices are the largest portion of Bionostics’ business.  Bionostics recently launched coagulation device control products and is developing new controls for other growing diagnostic uses, particularly controls for cholesterol and HbA1c point-of-care testing (POCT) devices. Bionostics is positioned to take advantage of continuing growth driven by the increasing prevalence of diabetes and other diseases, the migration of diagnostic testing from the laboratory to the operating room, bedside, clinic, and home points of care, the implementation of controls regulations in global markets and new controls being required for emerging diagnostic and (POCT) products.

Jessica Achtsam
Jessica Achtsam is an associate in our Orange County office. She practices intellectual property law with an emphasis on U.S. and foreign patent prosecution and patent portfolio management in the medical device and biotechnology fields. Ms. Achtsam currently represents clients in a variety of technologies, including wound care devices and methods, ophthalmic devices and methods, and other medical device related technologies. Before attending law school, Ms. Achtsam worked in research and development for Rules-Based Medicine, Inc. (now Myriad RBM, Inc.) in the area of biomarker testing development. During law school, Ms. Achtsam served as the Volume 20 Editor-in-Chief of the Texas Intellectual Property Law Journal.
View all posts published by Jessica Achtsam »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.